Dose-ranging Study of Oral PHA-022121 for Prophylaxis Against Angioedema Attacks in Patients With Hereditary Angioedema Type I or Type II

NCT05047185 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

34

Enrollment

INDUSTRY

Sponsor class

Conditions

Hereditary Angioedema
Hereditary Angioedema Type I
Hereditary Angioedema Type II
Hereditary Angioedema Types I and II
Hereditary Angioedema Attack
Hereditary Angioedema With C1 Esterase Inhibitor Deficiency
Hereditary Angioedema - Type 1
Hereditary Angioedema - Type 2
C1 Esterase Inhibitor Deficiency
C1 Inhibitor Deficiency

Interventions

DRUG: Deucrictibant low dose
DRUG: Deucrictibant high dose
DRUG: Placebo

Sponsor

Pharvaris Netherlands B.V.